Serum galectin-3 levels are decreased in schizophrenia

Abstract

Objective: To determine whether changes in serum galectin-3 (gal-3) concentrations in schizophrenia patients have etiopathogenetic importance. Since very little research has assessed the connection between galectins and schizophrenia, we wanted to examine alterations in the inflammatory marker gal-3 in schizophrenia and investigate possible correlations between clinical symptomatology and serum concentrations. Methods: Forty-eight schizophrenia patients and 44 healthy controls were included in this study. The Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for the Assessment of Negative Symptoms (SANS) were administered to determine symptom severity. Venous blood samples were collected, and serum gal-3 levels were measured. Results: Mean serum gal-3 levels were significantly lower in schizophrenia patients, and there were no significant differences in age or sex with the control group. There was also a significant positive correlation between serum gal-3 concentrations and negative schizophrenia symptoms according to the SANS. Conclusion:The results indicate that gal-3 is decreased in schizophrenia patients, which could contribute to inflammation in the pathogenesis of schizophrenia.

Assessment of serum galectin-3 levels in acute rheumatic fever

“…Although there are some controversies, significantly decreased levels of galectin-3 have been reported in schizophrenia. 25 Galectin-1 and galectin-3 levels have been studied in patients with rheumatoid arthritis, and galectin-1 levels have been reported to be significantly increased. 22 In the same study, galectin-3 levels were significantly decreased, and were not correlated with the erythrocyte sedimentation rate as similar to our study.…”